Cargando…
Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treat...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140180/ https://www.ncbi.nlm.nih.gov/pubmed/31643101 http://dx.doi.org/10.1002/jbmr.3903 |
_version_ | 1783518936825856000 |
---|---|
author | Li, Xiang Jiang, Yan Huo, Li Wu, Huanwen Liu, Yong Jin, Jin Yu, Wei Lv, Wei Zhou, Lian Xia, Yu Wang, Ou Li, Mei Xing, Xiaoping Chi, Yue Jiajue, Ruizhi Cui, Lijia Meng, Xunwu Xia, Weibo |
author_facet | Li, Xiang Jiang, Yan Huo, Li Wu, Huanwen Liu, Yong Jin, Jin Yu, Wei Lv, Wei Zhou, Lian Xia, Yu Wang, Ou Li, Mei Xing, Xiaoping Chi, Yue Jiajue, Ruizhi Cui, Lijia Meng, Xunwu Xia, Weibo |
author_sort | Li, Xiang |
collection | PubMed |
description | Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue‐involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. |
format | Online Article Text |
id | pubmed-7140180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71401802020-04-08 Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study Li, Xiang Jiang, Yan Huo, Li Wu, Huanwen Liu, Yong Jin, Jin Yu, Wei Lv, Wei Zhou, Lian Xia, Yu Wang, Ou Li, Mei Xing, Xiaoping Chi, Yue Jiajue, Ruizhi Cui, Lijia Meng, Xunwu Xia, Weibo J Bone Miner Res Original Articles Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue‐involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2019-11-15 2020-03 /pmc/articles/PMC7140180/ /pubmed/31643101 http://dx.doi.org/10.1002/jbmr.3903 Text en © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Li, Xiang Jiang, Yan Huo, Li Wu, Huanwen Liu, Yong Jin, Jin Yu, Wei Lv, Wei Zhou, Lian Xia, Yu Wang, Ou Li, Mei Xing, Xiaoping Chi, Yue Jiajue, Ruizhi Cui, Lijia Meng, Xunwu Xia, Weibo Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study |
title | Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study |
title_full | Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study |
title_fullStr | Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study |
title_full_unstemmed | Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study |
title_short | Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study |
title_sort | nonremission and recurrent tumor‐induced osteomalacia: a retrospective study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140180/ https://www.ncbi.nlm.nih.gov/pubmed/31643101 http://dx.doi.org/10.1002/jbmr.3903 |
work_keys_str_mv | AT lixiang nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT jiangyan nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT huoli nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT wuhuanwen nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT liuyong nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT jinjin nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT yuwei nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT lvwei nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT zhoulian nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT xiayu nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT wangou nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT limei nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT xingxiaoping nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT chiyue nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT jiajueruizhi nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT cuilijia nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT mengxunwu nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy AT xiaweibo nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy |